Tocilizumab was used in one patient who developed recurrent CIP due to ICI re‐challenge (the level of IL‐6 in the serum of the patient increased significantly) and one patient with Grade 4 CIP (the patient's condition progressed rapidly and had to be intubated soon. Here, IL6 is linked to hereditary sensory and autonomic neuropathy.